Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms
- PMID: 15909462
Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms
Abstract
Background: Relief of climacteric symptoms is currently the main role of hormone therapy. However, vaginal bleeding complicating this therapy is among the leading causes for its early discontinuation.
Objectives: To assess the effect of a vaginal ring delivering estradiol and progesterone in postmenopausal women and to determine whether continuous administration can relieve climacteric symptoms, produce an acceptable pattern of vaginal bleeding and control endometrial proliferation.
Methods: Twenty-nine postmenopausal women with an intact uterus were studied. All had climacteric symptoms. The vaginal rings contained 0.36 g estradiol and either 3.6 g progesterone (high dose progesterone) or 1.8 g (low dose progesterone), and were kept in place for 4-6 months. Serum progesterone, estradiol and estrone were measured and endometrial thickness determined. All women kept a daily diary of bleeding/spotting and completed a questionnaire on climacteric symptoms at monthly intervals. The low dose progesterone group comprised 14 women and the high dose progesterone group 15 women.
Results: A total of 18 patients (9 in each group) completed the study. Mean levels of estradiol, estrone and progesterone were at their peak after 2 to 4 weeks. All rings were effective in alleviating vasomotor symptoms, although there was evidence of "escape from effect" in month 6. Endometrial thickness increased in 6 of the 29 women but biopsy in each case showed no evidence of hyperplasia. Of the 18 women who completed the study, 5 had amenorrhea throughout, 7 had amenorrhea after 3 months, and the remainder had one or two bleeding episodes after 3 months. Therapy was discontinued in 11 women.
Conclusions: A vaginal ring delivering estradiol and progesterone controlled climacteric symptoms, prevented endometrial proliferation, and provided an acceptable bleeding pattern. It should be viewed as a possible alternative for short-term estrogen-progesterone therapy.
Similar articles
-
Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.Acta Obstet Gynecol Scand. 1998 Aug;77(7):758-63. Acta Obstet Gynecol Scand. 1998. PMID: 9740525
-
Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women.Gynecol Endocrinol. 2003 Jun;17(3):247-54. Gynecol Endocrinol. 2003. PMID: 12857433
-
Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women.J Med Assoc Thai. 2000 Apr;83(4):407-16. J Med Assoc Thai. 2000. PMID: 10808701 Clinical Trial.
-
Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review.Eur J Contracept Reprod Health Care. 2003 Dec;8(4):217-24. Eur J Contracept Reprod Health Care. 2003. PMID: 15006269 Review.
-
Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis.Clin Ther. 1993 Nov-Dec;15(6):950-62; discussion 949. Clin Ther. 1993. PMID: 8111815 Review.
Cited by
-
Bioidentical hormones for women with vasomotor symptoms.Cochrane Database Syst Rev. 2016 Aug 1;2016(8):CD010407. doi: 10.1002/14651858.CD010407.pub2. Cochrane Database Syst Rev. 2016. PMID: 27479272 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources